Quercetin
The most researched natural senolytic. As the 'Q' in the Mayo Clinic's Dasatinib + Quercetin (D+Q) protocol, Quercetin has been validated in multiple human clinical trials for senescent cell clearance — diabetic kidney disease, pulmonary fibrosis, and Alzheimer's feasibility studies. Daily low-dose use provides potent antihistamine, anti-inflammatory, and mitochondrial biogenesis support.
Reviewed & fact-checked by
BiohackingHub Research TeamEditorial Research Team · Last updated: April 23, 2026
Medical Disclaimer: The information on this page is for educational and research purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
What Is Quercetin?
A plant flavonoid found in onions, apples, capers, and berries — but calling Quercetin "just a flavonoid" undersells it dramatically. It's the active partner in the only senolytic regimen with published human clinical trial data, and it doubles as one of the most effective natural antihistamines available.
Two completely different use cases, two completely different dosing strategies, one molecule.
The Senolytic Story
In 2015, James Kirkland's group at Mayo Clinic made a discovery that reframed how we think about ageing: senescent cells — dysfunctional "zombie cells" that stop dividing but refuse to die — depend on specific pro-survival pathways. Block those pathways, and senescent cells selectively self-destruct while healthy cells are unaffected.
Quercetin inhibits BCL-xL, the anti-apoptotic protein that keeps senescent cells alive. Dasatinib covers different ground — Src family kinases, ephrin receptors, PI3K. Neither compound alone matches the combination's efficacy.
Published human trials:
- Hickson 2019: 9 diabetic kidney disease patients. 3 days of D+Q reduced senescent cell burden in skin and adipose biopsies. First proof that senolytics work in humans.
- Justice 2019: 14 IPF patients. 3 D+Q cycles improved physical function in a progressive, fatal disease.
- Gonzales 2023 (Nature Medicine): Mild Alzheimer's. D+Q crosses the blood-brain barrier — measurable in CSF — and reduces CNS senescence markers.
- Mayo 2025 (eBioMedicine): The latest. Older adults at Alzheimer's risk. 100mg Dasatinib + 1250mg Quercetin, 2 days every 2 weeks, 12 weeks. Safe. Preliminary cognitive and gait improvements.
Why Pulsed, Not Daily?
Senescent cells aren't proliferating — they sit there secreting inflammatory signals. You don't need constant drug exposure. Hit them hard for 2 days, wait weeks for new ones to accumulate, repeat.
Continuous daily dosing of 1000mg+ Quercetin is NOT a senolytic regimen. It's an anti-inflammatory regimen that happens to use the same molecule. The peak plasma concentration required for BCL-xL inhibition needs the pulsed approach.
The Bioavailability Problem
Standard quercetin aglycone has approximately 1% oral bioavailability. Of 1000mg swallowed, ~10mg reaches circulation. That's the elephant in the room for every quercetin supplement on the shelf.
For senolytic applications, this is a dealbreaker unless you address it:
| Form | Bioavailability | Use Case |
|---|---|---|
| Standard aglycone | ~1% | Mostly ineffective at stated dose |
| Quercetin + Bromelain | ~5–10% | Budget option, modest improvement |
| EMIQ (isoquercitrin) | 10–40x vs aglycone | Good for daily anti-inflammatory |
| Quercetin Phytosome (Quercefit) | ~20x vs aglycone | Preferred for senolytic protocols |
If you're spending money on quercetin and not using an enhanced-bioavailability form, most of it is passing through unabsorbed.
Daily Use: Beyond Senolytics
Even at sub-senolytic daily doses (500–1000mg enhanced form), quercetin pulls its weight:
Allergy/histamine control: Mast cell stabilisation comparable to OTC antihistamines in some comparative trials. The mechanism — direct inhibition of histamine release — is well characterised.
Blood pressure: 3–5 mmHg reduction in hypertensive individuals across multiple trials.
Mitochondrial biogenesis: AMPK/SIRT1/PGC-1a activation — quercetin stimulates new mitochondrial production.
Zinc ionophore: Transports zinc into cells where intracellular zinc inhibits viral RNA polymerase. This is the mechanistic basis for quercetin's antiviral reputation.
Exercise performance: Meta-analyses show modest VO2max improvements — subtle but consistent.
The Dasatinib Access Question
Dasatinib is a prescription tyrosine kinase inhibitor for chronic myeloid leukaemia. Getting it for senolytic use requires an off-label prescription from a longevity-oriented physician, baseline bloodwork (CBC, liver enzymes), and understanding of potential side effects.
Quercetin alone has senolytic activity, but the D+Q synergy is substantially greater. Some practitioners use Fisetin as a natural-only alternative — it has stronger standalone senolytic evidence in preclinical models, though without D+Q's human trial validation.
Related Research
Stacking Interactions
How Quercetin interacts with other compounds
Prescription required for Dasatinib. 100mg Dasatinib + 1250mg Quercetin for 2 consecutive days, every 2-4 weeks. Physician oversight essential.
Some practitioners alternate Fisetin and Quercetin senolytic cycles rather than combining them.
Daily anti-inflammatory stack. Both benefit from fat co-administration.
Can be used concurrently without timing concerns.
Safety Profile — Tier A
Well-tolerated — strong human evidence
Contraindications
- ●Anticoagulant therapy (may potentiate warfarin) — consult physician
- ●Kidney disease at doses above 1g/day
- ●Pregnancy and breastfeeding — insufficient safety data
Side Effects
- ●Excellent safety profile at standard doses
- ●Mild GI upset at doses above 1g/day
- ●Headache in sensitive individuals
- ●At senolytic doses (1250mg): transient fatigue during D+Q dosing days